Vivani Medical, Inc. reported a net loss of $6.4 million for the three months ended June 30, 2026, a decrease from the $7.1 million loss recorded in the same period last year. For the six months ended June 30, 2026, the company’s net loss was $13.2 million, slightly down from $13.4 million in the prior year. Operating expenses for the second quarter totaled $6.9 million, down from $7.5 million in the same quarter of 2025, primarily due to reduced research and development costs. The company’s cash and cash equivalents increased to $19.9 million as of June 30, 2026, compared to $16.2 million at the end of 2025.

Vivani Medical has made significant strides in its operational strategy, including the completion of dosing for all participants in the SLIM-1 trial of its NPM-139 (semaglutide) implant, with topline data expected in November 2026. The company is also pursuing a merger agreement with ClearOne, Inc., which aims to raise $10 million to $15 million to support its Cortigent subsidiary, focused on neurostimulation technology. This merger is anticipated to close in the third quarter of 2026, subject to certain conditions.

The company’s workforce has expanded, with 89.4 million shares of common stock outstanding as of June 30, 2026, up from 76.4 million shares at the end of 2025. Vivani’s research and development efforts are focused on its proprietary NanoPortal technology, which aims to address chronic diseases through long-acting drug delivery systems. The company has not yet generated revenue from product sales, and it continues to rely on equity financing to fund its operations, raising $15.5 million in the first half of 2026 through various stock offerings.

Looking ahead, Vivani Medical anticipates ongoing operating losses as it continues to invest in clinical trials and product development. The company has indicated that its existing cash reserves are expected to fund operations through the second quarter of 2027, but it will require additional capital to sustain its business beyond that point. The company faces various risks, including regulatory challenges, competition, and the need for successful clinical trial outcomes to achieve future profitability.

About Vivani Medical, Inc.

Vivani Medical, Inc. is a biopharmaceutical company developing proprietary NanoPortal subdermal drug implants for long-acting delivery of medicines targeting chronic diseases like obesity and type 2 diabetes. Its platform aims to improve medication adherence and tolerability through miniaturized, controlled-release implants, primarily using GLP-1 therapeutics. The company focuses on clinical-stage programs, strategic collaborations, and intellectual property to revolutionize chronic disease treatment.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov